Method of Genetic Analysis in Genodermatoses (GENODERM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03873285|
Recruitment Status : Recruiting
First Posted : March 13, 2019
Last Update Posted : April 15, 2019
|Condition or disease||Intervention/treatment||Phase|
|Genodermatosis Rare Genetic Disease With Cutaneous Expression||Genetic: Genetic diagnostic by mendeliome or genome||Not Applicable|
Interventional multicenter prospective study. Patients will be examined by a dermatologist to describe and identify the various skin lesions Collaboration with the geneticist team: clinical examination for relevant cases Patient records will be consulted. Relevant medical information, biological examinations and other complementary examinations will be studied.
A blood sample (10 ml in EDTA tube) will be collected from the patient and his/her parents to store DNA for mediome and genome.
A written parental and child consent (if age-appropriate) will be obtained and a study information sheet will be signed. They will also sign the usual genetic consent request for mendeliome, genome and transcriptome on culture of fibroblasts.
A 4 mm punch skin biopsy (healthy or damaged depending on phenotype and indication) will be performed according to the standard technique.
The fibroblast culture will be performed routinely by the Genetics Center Transcriptome will be done according to the processes set up at the Genetics Center Mendeliome analysis
- Allow the analysis of 4000 rare disease genes
- Will be performed according to routine analyzes of the genetics lab
- Uses the Highlander tools (web)
- Use of de novo filters, autosomal recessive, heterozygous compound, X linked, strong variant (LOF and canonical splice sites)
- Use of rarer filters: exomic or gene deletion, splicing (+/- 12 base pairs around exons)
- In unexplained severe cases, a genome supplemented with the 10Xgenomics method and a transcriptome of fibroblasts will be realized. This double strategy afford to get a genome of high interpretative quality. Genome analysis by the 10Xgenomics method (https://www.10xgenomics.com )
- This method allows us to deconvolate haplotypes and allows the analysis of 16,000 other complementary genes and to obtain precisely defined structural variants.
- The transcriptome will better assess the genomic effects on gene expression.
- The genome and transcriptome will also assess the presence of deep intron mutations and their effect on splicing, and will be a sustainable resource for other long-term projects (analysis of non-coding regions, microRNAs, etc.)
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Development of a Genetic Analysis Method by Mendeliomes and Genomes in the Diagnosis of Genodermatoses and Rare Genetic Diseases With Cutaneous Expression|
|Actual Study Start Date :||November 27, 2018|
|Estimated Primary Completion Date :||November 2021|
|Estimated Study Completion Date :||November 2021|
Experimental: Genodermatosis patients
Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
Genetic: Genetic diagnostic by mendeliome or genome
For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
- Genetic diagnostic by mendeliome [ Time Frame: At time of clinical diagnosis of genodermatosis ]Proportion of patients for whom a genetic diagnosis has been established using the mendeliome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
- Genetic diagnostic by genome [ Time Frame: At time of clinical diagnosis of genodermatosis ]Proportion of patients for whom a genetic diagnosis has been established using the genome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
- Genetic diagnostic by fibroblast transcriptome [ Time Frame: At time of clinical diagnosis of genodermatosis ]Proportion of patients for whom a genetic diagnosis has been established using the fibroblast transcriptome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
- Relevance of dermatological symptoms [ Time Frame: At time of clinical diagnosis of genodermatosis ]Correlation between dermatological signs and symptoms and a genetic diagnosis established by the mendelioma, genome and transcriptome method
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03873285
|Contact: Deborah Salik, MD||0032 2 477 31 20||Deborah.firstname.lastname@example.org|
|Contact: Guillaume Smits, MD PhD||Guillaume.email@example.com|
|Hôpital Universitaire Des Enfants Rein Fabiola||Recruiting|
|Brussels, Belgium, 1020|
|Contact: Deborah Salik, MD 0032 2 477 31 20 Deborah.firstname.lastname@example.org|
|Principal Investigator: Deborah Salik, MD|
|Principal Investigator:||Deborah Salik, MD||Hôpital Universitaire Des Enfants Rein Fabiola|